Top

17-10-2017 | Breast cancer | Article

Serum selenium levels predict survival after breast cancer

Journal: Breast Cancer Research and Treatment

Authors: J. Lubinski, W. Marciniak, M. Muszynska, T. Huzarski, J. Gronwald, C. Cybulski, A. Jakubowska, T. Debniak, M. Falco, J. Kladny, J. Kotsopoulos, P. Sun, S. A. Narod

Publisher: Springer US

Abstract

Background

Studies have reported an inverse relationship between serum selenium levels and cancer incidence, but the impact of low serum selenium status on survival after a diagnosis of breast cancer has not been established.

Methods

We obtained a blood sample from 546 women diagnosed with a first primary invasive breast cancer between 2008 and 2015 in the region of Szczecin, Poland. Blood was collected after diagnosis, but prior to treatment. Serum selenium was quantified by mass spectroscopy and each patient was assigned to one of four categories (quartiles) based on the distribution in the entire cohort. Patients were followed from diagnosis to death over a mean follow-up of 3.8 years. Vital status was obtained by linkage to the Polish National Death Registry.

Results

The 5-year overall actuarial survival was 68.1% for women in the lowest (< 64.4 µg/L) and 82.5% for those in the highest (> 81.0 µg/L) quartile of serum selenium. In an adjusted analysis, the hazard ratio for death was 2.49 (95%CI 1.53–4.04; P = 0.0002) for patients in the lowest quartile of serum selenium, compared to those in all other quartiles. The effect of low selenium on breast cancer-specific mortality was stronger for women who were past smokers (HR 6.03; 95%CI 1.96–18.6; P = 0.0002).

Conclusions

This study suggests that a selenium level in excess of 64.4 µg//L might be beneficial for women undergoing treatment for breast cancer and that selenium supplementation to achieve this level may favorably impact the outcome. Further studies are needed to confirm this association and to evaluate the impact of selenium supplementation on breast cancer survival among women with low post-diagnostic selenium levels.

Rayman MP (2012) Selenium and human health. Lancet 379(9822):1256–1268CrossRefPubMed

Vinceti M, Dennert G, Crespi CM et al (2014) Selenium for preventing cancer. Cochrane Database Syst Rev 3:CD005195PubMedCentral

Jaworska K, Gupta S, Durda K et al (2013) A low selenium level is associated with lung and laryngeal cancers. PLoS ONE 8(3):e59051CrossRefPubMedPubMedCentral

Laclaustra M, Stranges S, Navas-Acien A et al (2010) Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis 210(2):643–648CrossRefPubMedPubMedCentral

Brenner DR, Brockton NT, Kotsopoulos J et al (2016) Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control 27(4):459–472CrossRefPubMedPubMedCentral

Harris HR, Bergkvist L, Wolk A (2012) Selenium intake and breast cancer mortality in a cohort of Swedish women. Breast Cancer Res Treat 134(3):1269–1277CrossRefPubMed

Rayman MP (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64(4):527–542CrossRefPubMed

Rayman MP (2008) Food-chain selenium and human health: emphasis on intake. Br J Nutr 100(2):254–268PubMed

Johnson CC, Fordyce FM, Rayman MP (2010) Symposium on ‘Geographical and geological influences on nutrition’: factors controlling the distribution of selenium in the environment and their impact on health and nutrition. Proc Nutr Soc 69(1):119–132CrossRefPubMed

10.

Hurst R, Collings R, Harvey LJ et al (2013) EURRECA-Estimating selenium requirements for deriving dietary reference values. Crit Rev Food Sci Nutr 53(10):1077–1096CrossRefPubMed

11.

Combs GF Jr (2015) Biomarkers of selenium status. Nutrients 7(4):2209–2236CrossRefPubMedPubMedCentral

12.

Bates CJ, Thane CW, Prentice A et al (2002) Selenium status and its correlates in a British national diet and nutrition survey: people aged 65 years and over. J Trace Elem Med Biol 16(1):1–8CrossRefPubMed

13.

Davis CD, Tsuji PA, Milner JA (2012) Selenoproteins and cancer prevention. Annu Rev Nutr 32:73–95CrossRefPubMed

14.

Steinbrenner H, Speckmann B, Sies H (2013) Toward understanding success and failures in the use of selenium for cancer prevention. Antioxid Redox Signal 19(2):181–191CrossRefPubMedPubMedCentral

15.

Hatfield DL, Tsuji PA, Carlson BA et al (2014) Selenium and selenocysteine: roles in cancer, health, and development. Trends Biochem Sci 39(3):112–120CrossRefPubMedPubMedCentral

16.

Klein EA, Thompson IM Jr, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549–1556CrossRefPubMedPubMedCentral

17.

Duffield-Lillico AJ, Dalkin BL, Reid ME et al (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91(7):608–612CrossRefPubMed

18.

Kristal AR, Darke AK, Morris JS et al (2014) Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 106(3):djt456CrossRefPubMedPubMedCentral

19.

Stranges S, Sieri S, Vinceti M et al (2010) A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health 10:564CrossRefPubMedPubMedCentral

20.

Levander OA (1977) Metabolic interrelationships between arsenic and selenium. Environ Health Perspect 19:159–164CrossRefPubMedPubMedCentral

21.

Chen Y, Hall M, Graziano JH et al (2007) A prospective study of blood selenium levels and the risk of arsenic-related premalignant skin lesions. Cancer Epidemiol Biomark Prev 16(2):207–213CrossRef

22.

Hunter D (1998) Biochemical indicators of dietary intake. In: Willett W (ed) Nutritional epidemiology: monographs in epidemiology and biostatistics. Oxford University Press, New York, pp 174–243